Project Grant R56DK149809
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $847,498 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate strategies for integrating deceased-donor-initiated kidney paired donation (DD-KPD) chains into the U.S. kidney allocation system. The project addresses the kidney shortage and stagnation in living donation by redirecting a small percentage of deceased...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $872,273 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to identify modifiable process delays in deceased donor kidney allocation through process mining analysis. The project applies process mining methodology to discover actual kidney placement workflows from data logs at multiple organ procurement organizations (OPOs). The research...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the Veterans Medical Research Foundation of San Diego $383,098 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The recipient will conduct research into kidney tubule dysfunction in APOL1-associated chronic kidney disease, with focus on developing and validating tubular biomarkers that capture kidney functions—nutrient reabsorption and toxin...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University (doing business as New York University School of Medicine) $1.674 million on September 24, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop an empirically-based, optimal prehabilitation program for kidney transplant candidates on hemodialysis. The research addresses a significant clinical need: of more than 140,000 people waiting for kidney...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University $1.65 million on September 15, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate and design a new kidney allocation policy permitting ABO-compatible transplants. The research addresses a persistent gap in the current U.S. kidney allocation system: high-sensitized patients with blood types B and O remain underserved despite the 2014 policy...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University School of Medicine $847,495 on February 19, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to build expert consensus on stratified kidney allocation design, estimate the policy impact of stratified allocation systems to assist policymakers, and investigate patient, care partner, and provider attitudes and perceptions regarding shared decision-making...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded New York University School of Medicine $877,742 on September 2, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to evaluate the effect of a state-wide centralized patient coaching program about live donor kidney transplantation. The award funds the Live Donor Champion (LDC) program, which educates end-stage kidney disease patients, their caregivers, and social...
- Federal Grant Award Summary The University of Tennessee Health Science Center received a $3.01 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded September 15, 2025, with completion targeted for August 31, 2029. This research project focuses on developing mitoprotective therapies to address acute kidney injury (AKI), a prevalent condition...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Washington University $766,951 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate imaging biomarkers for assessing high-risk deceased donor kidneys slated for transplantation. The project addresses kidney shortage by improving the accuracy of kidney quality assessment, reducing the approximately 2,500 procured kidneys discarded...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Research Foundation for the State University of New York $327,450 on August 20, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct research on reducing geographic disparity in access to deceased donor kidney transplantation. The recipient will employ advanced statistical methods, artificial intelligence, and operations research to understand complex dynamics...
The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Tennessee $639,022 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847, Assistance Type: Project Grant). The award funds a one-year research study designed to promote HIV-to-HIV kidney transplantation as standard-of-care clinical practice in the new regulatory environment following November 2024 modifications to transplant eligibility criteria. The study will establish a Community Advisory Board and Provider Advisory Board, explore perceived barriers and facilitators to organ donation among people with HIV and healthcare providers, and survey healthcare providers about contemporary implementation of HIV-to-HIV kidney transplantation. The research addresses a documented gap: while over 90 percent of Americans support organ donation, only 50 percent are registered donors, with the disparity more pronounced among people with HIV—80 percent support donation but only 21 percent are registered. Kidney transplantation remains the optimal treatment for end-stage kidney disease, the most prevalent end-stage organ condition, yet organ supply remains insufficient to meet demand. Period of performance runs September 1, 2026, through August 31, 2027. Place of performance is Knoxville, Tennessee.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $639.0k | 8/24/26 |